Discovery of cytosine deaminases enables base-resolution methylome mapping using a single enzyme

Abstract

Abstract Cytosine deaminases have important uses in the detection of epigenetic modifications and in genome editing. However, the range of applications of deaminases is limited by a small number of well characterized enzymes. To expand the toolkit of deaminases, we developed an in-vitro approach that bypasses a major hurdle with their severe toxicity in expression hosts. We systematically assayed the activity of 175 putative cytosine deaminases on an unprecedented variety of substrates with epigenetically relevant base modifications. We found enzymes with high activity on double- and single-stranded DNA in various sequence contexts including novel CpG-specific deaminases, as well as enzymes without sequence preference. We also report, for the first time, enzymes that do not deaminate modified cytosines. The remarkable diversity of cytosine deaminases opens new avenues for biotechnological and medical applications. Using a newly discovered non-specific, modification-sensitive double-stranded DNA deaminase, we developed a nondestructive single-enzyme 5-methylctyosine sequencing (SEM-seq) method. SEM-seq enables accurate, high-coverage, base-resolution methylome mapping of scarce biological material including clinically relevant cell-free DNA (cfDNA) and single-cell equivalent 10 pg input DNA. Using SEM-seq, we generated highly reproducible base-resolution 5mC maps, accounting for nearly 80% of CpG islands for a low input human cfDNA sample offering valuable information for identifying potential biomarkers for detection of early-stage cancer and other diseases. This streamlined protocol will enable robust, high-throughput, high-coverage epigenome profiling of challenging samples in research and clinical settings.